

Novel and classical molecular pathways identified in pituitary tumorigenesis using mRNA profiling.

R Formosa¹, J Borg³, J Vassallo ^{1,2}

Department of Medicine, University of Malta Medical School, Msida, Malta, ²Neuroendocrine Clinic, Mater Dei Hospital, Msida, Malta; 3 Department of Applied Biomedical Sciences, Faculty of Health Science, University of Malta, Msida, Malta.


SCOPE


To identify novel molecular pathways involved in pituitary tumorigenesis using mRNA expression profiles.

METHODS

- RNA extracted from 8 pituitary tumours (5 NFPA, 2 GH-secreting tumours, 1 Prolactin/TSH- co-secreting) and pooled normal pituitary control RNA were used for microarray RNA expression analysis on Affymetrix HuGene 1.0 ST Chip.
- Microarray data was analyzed using GeneScript GX 11.0 and network analysis was carries out using the Ingenuity Pathway Analysis (IPA) software.
- Data from microarrays was verified using RNA from 30 pituitary tumours (20 NFPA, 6 GH-secreting, 2 PRL-secreting and 2 ACTH-secreting tumours) using quantitative PCR of key genes involved in the networks identified by the IPA.


RESULTS





CONCLUSIONS

- Microarrays coupled with qPCR are a useful tool in characterizing tumour types.
 - Classical pathways were confirmed by microarray and IPA, namely the cAMP signalling, PI3K cascade and Wnt signalling pathways [1,2,3]
- Wnt pathway inhibitors are greatly down-regulated, however, canonical signalling through $\beta\text{-catenin}$ appears unaltered.
 - Novel pathway identified include the AHR signalling, GABA receptor signalling and p53 signalling pathways among others.



nia A, Mantovani G, Spada A. 2012. cAMP pathway and pituitary tumoriç

² Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJ, Cook RJ, Little NS, Clifton-Bligh RJ, Robinson BG, McDonald KL. 2008. Wnt pathw inhibitors are strongly down-regulated in pituitary turnours.

³ Rubinfeld H, Shimon I. 2012. PI3K/Akt/mTOR and Raf/MEK/ERK signalling pathway perturbations in non-functioning pituitary adenomas. Endocrine. 42(2), 285-291.

The Research was funded by the UoM Research Fund Committee Allocation (PHBRP07-02) and Faculty of Medicine and Surgery funds (MDSIN08-22)